Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.
about
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Treatment strategies for DNA repair-deficient prostate cancer.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction.Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Immunotargeting and personalized therapies in genitourinary cancers.Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancerAndrogen deprivation and immunotherapy for the treatment of prostate cancerElimination of CD4HLA-G T cells overcomes castration-resistance in prostate cancer therapy
P2860
Q37676065-CC7600BD-DC60-46BC-BAD2-0AD6A20E9026Q38635366-1FDE1D73-75A2-461A-AFCE-2CA408747729Q38779877-96A18884-72A7-4030-9ED9-C7C6445639B5Q38962923-72EBC673-2072-4409-A1D1-E65B4348EDF5Q39093352-D3769C1F-0D60-433C-A620-531677C12743Q39345771-288BD4DF-A78B-4596-A3E1-81D3668302B1Q39438805-80A2C529-720B-469B-A844-3D236CA66923Q47094315-54E44770-E332-4466-95A7-9B3BFE2FC9AEQ47757361-667D82F2-2ACD-4E03-BCB2-B2BA37D29F3FQ48133624-A63DA7ED-2F34-4C95-B52A-2D4DD492849FQ48229904-C91F60C2-0FDA-4A40-A6E0-8092B7A2E12CQ52587537-F9B5D584-30CE-4E0E-9A0E-41848349DEB5Q55079680-4CB42512-BE17-40A9-94F1-CD97F2C05ECEQ56892705-B67E3A25-A66A-4F79-AB3F-B38A24C15DB9Q57115565-600028D0-5B6C-4506-8FDB-02F0535D7FF8Q57293807-E49E7965-38E2-4499-8593-38742C11D4B1
P2860
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Androgen receptor antagonists ...... eading to early tumor relapse.
@en
type
label
Androgen receptor antagonists ...... eading to early tumor relapse.
@en
prefLabel
Androgen receptor antagonists ...... eading to early tumor relapse.
@en
P2093
P2860
P1476
Androgen receptor antagonists ...... eading to early tumor relapse.
@en
P2093
P2860
P304
P356
10.1126/SCITRANSLMED.AAD5659
P407
P50
P577
2016-04-01T00:00:00Z